NIH Statement: Changing the Culture of Science to End Sexual Harassment

Last week, NIH Director Francis S. Collins issued a statement about the pervasive problem of sexual harassment in science and reaffirmed NIH’s commitment to address it. He noted that NIH is working to bolster its policies and practices to foster a culture of respect wherever NIH research activities are conducted, and to ensure that sexual harassment is not tolerated or ignored.

NIH has launched a new website on anti-sexual harassment activities. I encourage you to explore the site and become familiar with NIH’s policies, practices, and initiatives.

Consistent with NIGMS’ strong commitment to research training, the Institute recently announced that applications for our predoctoral T32 training programs must include in their required institutional support letters information about the institution’s policies and procedures to prevent discriminatory harassment and respond appropriately to allegations or findings of discriminatory harassment. Moving forward, NIGMS will require this information in institutional support letters for applications for all of our training programs.

Lasker Awards Honor Three NIGMS Grantees

We are delighted that three long-time NIGMS grantees have been recognized by the 2018 Lasker Awards Link to external web site. The awards highlight fundamental biological discoveries to draw attention to the importance of public support of science.

  • Michael Grunstein of the University of California, Los Angeles, and C. David Allis of Rockefeller University, received the 2018 Albert Lasker Basic Medical Research Award for “discoveries elucidating how gene expression is influenced by chemical modifications of histones—the proteins that package DNA within chromosomes.” NIGMS funded Grunstein’s work on the establishment and spreading of silent chromatin from 1977 to 2012. His research led to the generation of the first histone mutations in yeast and the first demonstration that chemical modification of specific ends of histones could turn gene expression on or off. Allis identified and characterized enzymes that add, remove, and read histone modifications. His work led to the hypothesis of a histone code that, when mis-read, can lead to disease. NIGMS has funded Allis since 1988.
  • Joan Argetsinger Steitz of Yale University received the 2018 Lasker-Koshland Special Achievement Award in Medical Science for “four decades of leadership in biomedical science—exemplified by pioneering discoveries in RNA biology, generous mentorship of budding scientists, and vigorous and passionate support of women in science.” Steitz’s pioneering research helped reveal the function of small pieces of RNA that are not used for making proteins. These molecules, including small nuclear ribonucleoproteins (snRNPs), help regulate gene activity. In doing so, they—like histone modifications—have a major impact on health and disease. NIGMS funded her research from 1975 to 2014. The Lasker-Koshland Award further recognizes Steitz’s long record of mentoring the next generation of scientific leaders and her effective and tireless work as an advocate for women in science.

We congratulate all of the recipients on these well-deserved honors.

Wanted: Program Director, Pharmacological and Physiological Sciences Branch

We’re recruiting for an accomplished scientist with experience in the pharmacological sciences to join the Pharmacological and Physiological Sciences (PPS) Branch of the Division of Pharmacology, Physiology, and Biological Chemistry. The successful applicant will have responsibility for scientific and administrative management of a portfolio of grants, both research and training, in the Division.

The PPS Branch supports research studies ranging from the molecular to cellular to organismal, which can be basic or clinical in nature. This position offers stewardship of grant awards related to modern approaches to examining the effects of drugs on the body and the body’s effects on drugs, as well as how these effects vary from individual to individual. This includes investigations of the absorption, transport, distribution, metabolism, biotransformation, toxicity, and excretion of drugs, as well as determinants and models of pharmacokinetics. The portfolio also includes investigation of drug delivery strategies and the packaging and delivery of molecules and biologics, with an emphasis on drug release and kinetics.

Continue reading